Investment Rating - The investment rating for the company is "Buy" (首次) [5] Core Views - The company is positioned as a leading domestic probiotic brand, benefiting from both category penetration and domestic substitution opportunities [5][7] - The Chinese probiotic market is expected to grow significantly, with a projected market size of approximately 138 billion RMB in 2024, driven by health consumption trends and expanding application scenarios [7] - The company has successfully broken the monopoly of high-end strains held by foreign companies and is expanding its downstream coverage in sectors such as food and beverages, health products, etc. [7] - The recent FDA GRAS certification for the company's star strain opens up new market opportunities, particularly in the weight loss sector [7] Financial Summary - Revenue projections for the company are as follows: - 2023: 299 million RMB - 2024: 303 million RMB - 2025E: 439 million RMB - 2026E: 551 million RMB - 2027E: 691 million RMB - The expected growth rates for revenue are 1.19% in 2024, 44.85% in 2025, 25.65% in 2026, and 25.36% in 2027 [6][8] - The projected net profit for the company is as follows: - 2023: 93 million RMB - 2024: 94 million RMB - 2025E: 128 million RMB - 2026E: 168 million RMB - 2027E: 210 million RMB - The expected growth rates for net profit are 0.94% in 2024, 35.90% in 2025, 31.35% in 2026, and 24.48% in 2027 [6][8] Valuation Metrics - The projected P/E ratios for the company are as follows: - 2025E: 34.93 - 2026E: 26.60 - 2027E: 21.37 [6][8] - The average P/E of comparable companies is estimated at 35X for 2025, indicating a favorable growth outlook for the company [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [8] Core Views - The company's probiotic business shows steady growth, with a remarkable revenue performance in Q1 2025 [8] - The company reported a slight decline in 2024 performance but anticipates accelerated revenue growth in 2025 due to strategic transformations and new customer acquisitions [8] Financial Summary - Total revenue for 2024 is projected at 303 million, with a year-on-year growth of 1.19% [8] - Net profit attributable to shareholders for 2024 is expected to be 94.36 million, reflecting a year-on-year increase of 0.94% [8] - The company forecasts a significant revenue increase in 2025, with total revenue expected to reach 434.57 million, representing a year-on-year growth of 43.52% [8] - The earnings per share (EPS) for 2024 is estimated at 0.36 yuan, with projections of 0.47 yuan for 2025 [8] - The price-to-earnings (P/E) ratio is expected to decrease from 40.27 in 2024 to 30.55 in 2025 [8] Business Performance - The probiotic business is expected to maintain a strong growth momentum, with a projected revenue increase of 26% in Q1 2025 [8] - The animal and plant micro-ecological preparation business is anticipated to see a significant growth of over 200% year-on-year in Q1 2025 due to new factory production [8] - The company is optimizing its product structure, which has positively impacted its gross margin, although the animal and plant business has slightly dragged down profitability in Q1 2025 [8]